Tyler Zemla
Overview
Explore the profile of Tyler Zemla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McBane 2nd R, Loprinzi C, Zemla T, Tafur A, Sanfilippo K, Liu J, et al.
J Thromb Haemost
. 2024 Dec;
23(2):756.
PMID: 39709266
No abstract available.
2.
Chan J, Geyer S, Zemla T, Knopp M, Behr S, Pulsipher S, et al.
N Engl J Med
. 2024 Sep;
392(7):653-665.
PMID: 39282913
Background: Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear. Methods:...
3.
Cooley M, Schneider A, Barr Fritcher E, Milosevic D, Levy M, Bridgeman A, et al.
Hepatology
. 2024 Jun;
81(2):453-464.
PMID: 38905442
Background And Aims: Early identification of malignant biliary strictures (MBSs) is challenging, with up to 20% classified as indeterminants after preliminary testing and tissue sampling with endoscopic retrograde cholangiopancreatography. We...
4.
McBane 2nd R, Loprinzi C, Zemla T, Tafur A, Sanfilippo K, Liu J, et al.
J Thromb Haemost
. 2024 Mar;
22(6):1704-1714.
PMID: 38537780
Background: Cancer-associated venous thromboembolism (VTE) management guideline recommendations include continued therapeutic anticoagulation while active cancer persists. The Federal Drug Administration label for apixaban for secondary VTE prevention includes a dose...
5.
Emiloju O, Storandt M, Zemla T, Tran N, Jethwa K, Mahipal A, et al.
JCO Precis Oncol
. 2024 Jan;
8():e2300127.
PMID: 38237099
Purpose: Recurrence after curative-intent treatment occurs in 20%-50% of patients with stage II-IV colorectal cancer (CRC), underscoring the need for early detection of minimal residual disease (MRD) using circulating tumor...
6.
Brown J, Ma C, Shi Q, Zemla T, Couture F, Kuebler P, et al.
Cancer
. 2023 Aug;
129(23):3724-3734.
PMID: 37651160
Background: One in three patients with stage III colon cancer will experience tumor recurrence. It is uncertain whether physical activity during and after postoperative chemotherapy for stage III colon cancer...
7.
Hassan H, Chakrabarti S, Zemla T, Yin J, Wookey V, Prasai K, et al.
Eur J Surg Oncol
. 2023 Jul;
49(11):106994.
PMID: 37524649
Background: Most patients with localized cholangiocarcinoma (CCA) endure cancer relapse after curative resection underscoring the importance of systemic therapy. The current study attempts to determine the impact of perioperative chemotherapy...
8.
Wang Q, Ma C, Yuan C, Shi Q, Wolpin B, Zhang Y, et al.
Clin Cancer Res
. 2023 Jun;
29(14):2621-2630.
PMID: 37289007
Purpose: To assess whether higher plasma 25-hydroxyvitamin D [25(OH)D] is associated with improved outcomes in colon cancer and whether circulating inflammatory cytokines mediate such association. Experimental Design: Plasma samples were...
9.
Brown J, Ma C, Shi Q, Niedzwiecki D, Zemla T, Couture F, et al.
Br J Sports Med
. 2023 Mar;
57(15):965-971.
PMID: 36878665
Objective: We determined if postoperative physical activity prevents or delays cancer recurrence in patients with stage III colon cancer. Methods: This cohort study nested within a randomised trial enrolled 1696...
10.
Brown J, Ma C, Shi Q, Fuchs C, Meyer J, Niedzwiecki D, et al.
J Clin Oncol
. 2022 Aug;
41(2):243-254.
PMID: 35944235
Purpose: To determine the specific types, durations, and intensities of recreational physical activity associated with the greatest improvements in disease-free survival (DFS) of patients with colon cancer. Methods: We conducted...